BioMarin seeks to divest hemophilia A gene therapy Roctavian

[BioMarin]
hapabapa

* BioMarin Pharmaceutical (NASDAQ:BMRN [https://seekingalpha.com/symbol/BMRN]) said it will look to divest Roctavian (valoctocogene roxaparvovec), a one-time gene therapy for hemophilia A to focus more on its core treatments.
* Offloading Roctavian means the biotech will have seven marketed therapies. It most profitable treatment is Voxzogo (vosoritide) to treat achondroplasia, a rare form of dwarfism. In Q3, its accounted for $218M of $776M in total revenue. By comparison, Roctavian earned just $3M, down from $7M in the year-ago period.
* Part of the issue with Roctavian is its price tag. In 2023, when the drug was approved, BioMarin set the list price at $2.9M.
* BioMarin released its Q3 financial results after Monday's closing bell. It missed [https://seekingalpha.com/news/4508953-biomarin-pharmaceutical-non-gaap-eps-of-0_12-misses-by-0_19-revenue-of-776m-misses-by-4_43m] on both lines.
* In addition, the company cut its 2025 non-GAAP diluted EPS guidance to $3.50-$3.60 from $4.40-$4.55 made in August. Consensus is $3.84.

MORE ON BIOMARIN PHARMACEUTICAL

* BioMarin Pharmaceutical Inc. 2025 Q3 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4833790-biomarin-pharmaceutical-inc-2025-q3-results-earnings-call-presentation]
* BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks [https://seekingalpha.com/article/4826838-biomarin-valuation-growth-and-the-pipeline-may-outweigh-transcon-competition-and-regulatory-risks]
* BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript [https://seekingalpha.com/article/4821141-biomarin-pharmaceutical-inc-bmrn-presents-at-morgan-stanley-23rd-annual-global-healthcare]
* BioMarin Pharmaceutical Non-GAAP EPS of $0.12 misses by $0.19, revenue of $776M misses by $4.43M [https://seekingalpha.com/news/4508953-biomarin-pharmaceutical-non-gaap-eps-of-0_12-misses-by-0_19-revenue-of-776m-misses-by-4_43m]
* BioMarin Pharmaceutical Q3 2025 Earnings Preview [https://seekingalpha.com/news/4508250-biomarin-pharmaceutical-q3-2025-earnings-preview]